Furthermore, in the exploratory analyses, we identified that the benefit of SGLT2 inhibitors on AF risk reduction was significant in men and the non-Hispanic White group, as well as among the most susceptible individuals with established ASCVD or CKD. The gene discussed is SLC5A2; the disease is atrial fibrillation.